The purpose of this study is to evaluate the safety and efficacy of human umbilical cord mesenchymal stem cell(hUC-MSC) for cerebral hemorrhage sequela.

Human umbilical cord mesenchymal stem cells exhibit the potential to differentiate into neural cells, which have been confirmed in in vivo and in vitro experiments. There have been few clinical reports describing umbilical cord mesenchymal stem cells for treatment of cerebral hemorrhage.

To investigate the effects of hUC-MSC treatment for cerebral hemorrhage sequela, 20 patients with cerebral hemorrhage will be enrolled and receive 4 times of hUC-MSC transplantation.

Inclusion Criteria:

• Aged 40-70 intracerebral hemorrhage patient
• With stroke history of more than 3 months, less than 60 months
• National Institutes of Health stroke scale(NIHSS) score of 7 or more points
• Patient is stable (normal respiration, afebrile, BP less than mean arterial pressure of 125 mm of Hg, fasting blood sugar <7 mg, and normal urea/electrolytes for at least 48 hours.)

Exclusion Criteria:

• History of neurological disease, head injury or psychiatric disorder;
• Pregnant women;
• Impaired liver function, abnormal blood coagulation, AIDS, HIV, combine other tumor or special condition;
• Progressive apoplexy;
• With malignant tumors.